Mycobacterium tuberculosis antigen Ag85B-induced anti-melanoma immune response and its mechanism.doc

 PAGE \* MERGEFORMAT 7 Mycobacterium tuberculosis antigen Ag85B-induced anti-melanoma immune response and its mechanism Author: Wu Xuezhong, WEI Hai-ming, ZHENG Xiao-dong Jin-Teng Chuan Zhi-Gang Tian [Keywords:] pcDNA3 [Abstract] AIM: To study the antimelanoma immunity efficacy of Ag85B antigen gene therapy in vivo. METHODS: C57BL / 6 mice were inoculated sc with B16 cells, and 8 days later the mice were inoculated sc again with B16 cells (control group 1) , B16/pcDNA3 cells (control group 2) or B16/pcDNA3Ag85B cells (experimental group), respectively. Tumor volume, survival time, serum IFNγ level and IL4 level of 3 groups mice were observed. Antitumor activity of Ag85B was studied. RESULTS: From 12 to 23 day, the mean tumor volume of mice increased from 1.1058 cm3 and 09123 cm3 to 75983 cm3 and 5.8746 cm3 in the control group 1 and 2, respectively. But it increased from 05158 cm3 to 15080 cm3 in the experimental group. The mean survival time of mice was 241 days and 247 days in the control group 1 and 2, respectively. That was 278 days in the experimental group. Within 13 days after the last inoculation, the serum IFNγ level of all groups experienced increased (That increased to263ng / L, 230ng / L and 25.2ng / L in the control group1, 2 and the experimental group, respectively). Subsequently, the serum IFNγ level in the two control groups decreased (That decreased to 193 ng / L and 183 ng / L in the control group 1 and 2) while it still augmented in the experimental group (That increased to 465 ng / L). IL4 level was slightly but not significantly enhanced and then declined in all mice.CONCLUSION: Ag85B induced the increase of serum IFNγ level in the animals experiments, inhibited the tumor growth and prolonged the survival of the tumorbearing mice. [Keywords] pcDNA3Ag85B; B16 cell; C57BL / 6; tumor immunity [Abstract] Objective: To explore the Ag85B-induced anti-melanoma immune response in the role, and its feasibility for tumor immunotherapy. Metho